Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) is now available.
KYORIN Pharmaceutical has received regulatory approval from Japan’s Ministry of Health, Labour and Welfare for its new GeneSoC FluA/B Detection Kit, an in vitro diagnostic designed to rapidly detect and differentiate influenza A and B viruses when used with the company’s GeneSoC mini series analyzers. The kit offers higher detection sensitivity and shorter measurement time—around 15 minutes—than the currently marketed GeneSoC influenza test, reinforcing KYORIN’s strategy to expand its GeneSoC-based respiratory and infectious disease portfolio and support early, accurate influenza diagnosis at the point of care, although the impact on earnings for the fiscal year ending March 31, 2026, is expected to be negligible.
The most recent analyst rating on (JP:4569) stock is a Hold with a Yen1725.00 price target. To see the full list of analyst forecasts on KYORIN Pharmaceutical Co.,Ltd. stock, see the JP:4569 Stock Forecast page.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company focused on the development and commercialization of prescription drugs and in vitro diagnostic (IVD) products, with a particular emphasis on respiratory and infectious disease testing. Leveraging its GeneSoC platform of compact genetic analyzers and associated test kits, the company targets point-of-care testing (POCT) settings to support rapid, accurate diagnostics in clinical practice.
Average Trading Volume: 134,036
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen85.28B
For an in-depth examination of 4569 stock, go to TipRanks’ Overview page.